DRUG Bright Minds Biosciences Inc.

-

Bright Minds Biosciences Beat Consensus Estimates

Friday, August 14, 2026 · 12:00 AM ET

Bright Minds Biosciences (DRUG) reported a loss of $0.17 per share on revenue of $0.00 million for the fiscal third quarter ended June 2026. The consensus estimate was a loss of $1.39 per share. The company beat consensus estimates by 87.77%.

Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.17)
Earnings Whisper®
Consensus Estimate
($1.39)
Earnings Surprise
Earnings Growth67.9 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth